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Prostate and bladder
Gold seeds as ﬁducial markers for bladder localization during radiotherapy
M. Medina1, L. Vázquez1, E. Cespón2, I. Sapin˜a2, E. Comesan˜a2, J. Mata2, V. Mun˜oz1
1 Oncología Radioterápica, Hospital do Meixoeiro
2 Urología, Hospital do Meixoeiro
Introduction. Target localization and veriﬁcation of the treatment position is important for the accurate delivery of conformal
radiotherapy. The bladder in particular is a deformable structure whose shape and position continually varies throughout a
course of radiation treatment as a result of bladder ﬁlling. We report a case in which we used a novel technique in of organ
localization using gold seeds as ﬁducial markers that are implanted into the bladder using an applicator that is passed through
a rigid cystoscope.
Materials and methods. The procedure was performed in one patient with macroscopic residual disease in the CT, Cystoscopy with
positive biopsy after TUR. Under sedation, ﬁve seeds were implanted, 3 around of the tumour and 2 in the contralateral wall, after
sterilization with manually pre-loaded into the needle using an aseptic technique before the applicator was passed through the
cystoscope. The needle of the applicator was inserted into the bladder wall under direct visualization and the seeds implanted
via the use of a guidewire operated manually. With curative intention, after chemotherapy the treatment was performed using
3DCRT technique with high-energy photons from a linear accelerator with multiple ﬁelds with multileaf shaped coplanar and
isocentric. He was treated supine with the bladder empty into the ﬁrst and second phase and the third phase full bladder was
driven veriﬁcation and adjustments daily portal imaging with gold markers. Received a total dose of 61.2Gy in 1.8Gy fractions.
Treatment was uneventful. As remarkable toxicity intense dysuria and cystitis G2.
Conclusion. The use of ﬁducial markers for the guidance of radiation therapy for bladder cancer is safe and feasible and could
enhance the accuracy efﬁcacy of radiotherapy for this patients.
http://dx.doi.org/10.1016/j.rpor.2013.03.683
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Purpose. Low dose rate (LDR) prostate brachytherapy is an accepted, effective and safe therapy for localized prostate cancer. One
the other hand, treatment with temporary high dose rate (HDR) brachytherapy with 192-Ir as monotherapy has a number of
advantages compared to LDR. We analyze the technique followed in the Group of patients treated within the planned trial.
Methods and Material. From a biologic perspective, the low prostate cancer / favors a large dose per fraction in terms of cancer
control. At the same time, the / of the rectum and bladder favors larger doses per fraction to increase the therapeutic window,
thus improving controlwhile limiting toxicity. BesidesHDRbrachytherapy asmonotherapyhas anumber of advantages compared
to LDR. Medical staff are completely free from radiation exposure, no radioactivity or material is left in the body of the patient
after treatment, the overall treatment time is decreased from many months with LDR to several minutes with HDR and improves
the radiation dose distribution, secondary to the ability to control the source position accurately and vary the source dwell time
during treatment.
Results. All patients received one implant and one fraction of HDR. Fraction dosewas 20.5 Gy. Brachytherapy procedureswere done
under spinal anesthesia with the patient in the lithotomy position. A Foley catheter was placed. The needles were positioned by
transperineal placement under real time TRUS guidance using a template. Axial cross-sections were captured in 2mm steps and
transferred to the Treatment Planning Software. Prostate gland, normal structures (urethra and rectum) and needle positions
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were identiﬁed and mapped based on the ultrasound image. Dose optimization was done on the reconstructed applicator geom-
etry using dose point and manual optimization algorithms to determine dwell positions and times. To decrease rectal toxicity,
transperineal hyaluronic acid injection into the peri-rectal fat was used to consistently displace the rectal wall away from the
radiation sources in all patients. To decrease genitourinary toxicity, urethal hypothermia was used. The prostate without safety
margins was then deﬁned as the planning target volume (PTV) to be treated with the prescribed dose (PD). All patients were
discharged from the center on the same day of the procedure between 6-8 hours of implantation.
Conclusions. This treatment is feasible with advantages compared to LDR and HDR brachytherapy as monotherapy using the
fractionation schedule of 4 fractions administered 2 times daily during two days and may involve a change in the therapeutic
strategy of this tumor.
http://dx.doi.org/10.1016/j.rpor.2013.03.684
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Introduction. Image guide radiotherapy (IGRT), hialuronic acid inyection and Intensity Modulated Radiation Therapy (IMRT) are
an advantage strategy in moderate hypofractionated radiation therapy in prostate cancer.
Objective. To describe how IGRT, hialuronic (HA) acid inyection and IMRT have been incorporated to improve accurate and safety
for hypofractionated treatment in prostate cancer in our institution.
Methods. We investigated a moderate hypofractionated protocol to treat low and intermediate risk prostate cancer with dose-
escalated since 63Gy in 21 fractions (3Gy/day) until 52Gy in 13 fractions (4Gy/day). The procedure will be performed in lithotomy
position of the patient under sedation within 15–20min. Previously to treatment administration, transperineally and guided by
transrectal ultrasound, HA was placed in the perirectal fat, in order to protect the rectum and optimize the dose. In the same
procedure a ﬁducial internal marker (Visicoil®) was placed within the prostate gland. External infrared spheras were used during
the CT simulation. The treatment was realized with IMRT with “sliding windows”, in the Novalis Linac (Brainlab®), adapted to
stereotactic treatments. Daily veriﬁcation of the treatment was performed with IGRT Exactrac system, using a 6D robotic cough,
infrared camera and orthogonal X-rays. We have not seen side effects and not complications related to the injection or the
compound itself and ﬁducial internal marker (Visicoil®) placed. There is no toxicity in the fat tissue or in rectal function.
Conclusions. Moderate hypofractionated radiotherapy with IGRT (ﬁducial internal markers), HA inyection and IMRT, is a feasible,
safety and accurate treatment for low and intermediate risk prostate cancer.
http://dx.doi.org/10.1016/j.rpor.2013.03.685
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Introduction. After external radiotherapy laparoscopic radical prostatectomy can get similar control in prostatic cancer compared
with the standard radical prostatectomy, however it’s rarely permorfed. The use of brachytherapy as a curative treatment option
has increased in recent years. Likewise, the biochemical relapse and failure after radiotherapy is becoming increasingly common
and it’s considered a therapeutic challenge, especially in patients with local recurrence, low comorbidity, life expectancy of at
least 10 years, CT1-T2, Gleason <7 and preoperative PSA <10ng/ml.
Case report. A 65 years old male with a body mass index of 31.93kg/m2, with an initial PSA of 5.93ng/ml in 2007. Prostatic biopsy
determined a well-differentiated prostate adenocarcinoma Gleason 4 (2 + 2) in the left lobe, whereby the patient received external
radiotherapy by administering a total of 77.7 Gy, achieving a nadir PSA of 1.1 ng/ml in October 2007. Since then PSA levels started
rising up gradually reaching 3.6 ng/ml in August 2009. We think that the patient had a local recurrence, cause bone scintigraphy
was negative and MRI determined a nodule of 15 mm in the left lobe supporting neoplasia. A prostatic biopsy reported focus of
adenocarcinoma in the two lobes and changes attributable to radiation therapy. We present a video of radiotherapy laparoscopic
radical prostatectomy with a surgical time of 250min. The hospital stay was 5 days. The pathologic report determined a lobar
acinar adenocarcinoma (residual tumor), a high grade PIN, edges and vesicles respected, ductoacinar epithelial changes and
ﬁbrosis secondary to radiation therapy.
Conclusion. After external radiotherapy laparoscopic radical prostatectomy is a complex technique that can be offered to patients
with less comorbidity and life expectancy greater than 10 years. Based on the published data, good local control rates can be
reached with 30–50% recurrence-free survival and 70–77% speciﬁc-disease survival at 10 years.
http://dx.doi.org/10.1016/j.rpor.2013.03.686
